AXL Kinase Assay Kit

Catalog #
79711
$535 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The AXL Kinase Assay Kit is designed to measure AXL kinase activity for screening and profiling applications using ADP-Glo® Kinase Assay as a detection reagent. The AXL Kinase Assay Kit comes in a convenient 96-well format, with enough purified recombinant AXL enzyme, AXL substrate (IRS1-tide), ATP and kinase assay buffer for 100 enzyme reactions.

Need us to run inhibitor screens or profile your compounds against AXL? Check out our Kinase Screening Services.

Synonyms
AZF, AZFA, SP3, AZF1, ARK, JTK11, Tyro7, UFO, AXL receptor tyrosine kinase
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Supplied As
The AXL Kinase Assay Kit comes in a convenient 96-well format, with enough purified recombinant AXL enzyme, AXL substrate, ATP and kinase assay buffer for 100 enzyme reactions.
Materials Required But Not Supplied

ADP-Glo® Kinase Assay (Promega #V6930)
Dithiothreitol (DTT, 1 M; optional)
Microplate reader capable of reading luminescence
Adjustable micropipettor and sterile tips
30°C incubator

Format
Catalog Number Reagent Amount Storage
40180 AXL* 10 µg -80°C Avoid multiple freeze/thaw cycles!
79334 5x Kinase assay buffer 1.5 ml -20­°C
79686 ATP (500µM) 100 µl -20­°C
79519 10x IRS1-tide (1mg/ml) 500 µl -20­°C
79696 96-well plate, white 1 Room Temp.  

*The concentration of AXL is lot-specific and will be indicated on the tube containing the enzyme.

UniProt #
P30530
Background
AXL (TYRO7) is a receptor tyrosine kinase that is overexpressed in various forms of cancer, including breast, prostate, colorectal, and non-small cell cancers. AXL overexpression has been shown to encourage tumor progression and metastasis and to decrease the anti-tumor immune response, making AXL an attractive candidate for anticancer therapies.
References

1. Wu, X., Liu, X., Koul, S., Lee, C.Y., Zhang, Z., Halmos, B. AXL kinase as a novel target for cancer therapy. Oncotarget. 2014; 5(20):9546-63.

2. Rankin, E.B., Giaccia, A.J. The Receptor Tyrosine Kinase AXL in Cancer Progression. Cancers (Basel). 2016; 8(11):103.